Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA) Inhibition of proliferation and invasion of human ovarian cancer cells by Wilhelm, O. et al.
ELSEVIER 
FEBS Letters 337 (1994) 131-134 LET7=ERS 
FEBS 13505 
Recombinant soluble urokinase receptor as a scavenger 
for urokinase-type plasminogen activator (UPA) 
inhibition of proliferation and invasion of human ovarian cancer cells 
0. ~~l~elrna~*, U. Weidleb, S. HGhl”, P, Rettenberge~, M. ~c~mitta, H. GraefP 
Received 22 October 1993: revised version received 26 November 1993 
Abstract 
A recombinant soluble human urokinase receptor comprising amino acids l-277 was cloned and transfected into CHO ceils. The mutant protein 
(me-uPAR&, purified from the CHO cell supernatant by affinity chromatography on immobilized urokinase &PA), in a four-fold excess, completely 
abolished the binding of FITC-labeled pro-uPA to the human ovarian cancer cell line, OV-MZ-6. This invasive and tumo~genic ancer cell line 
expresses uPA, its inhibitor PA&l, and the high-affinity receptor for uPA, uPAR. Ret-uPAR,,, si~ificantly reduced the proliferation of OV-MZ-6 
cells in a concentration-dependent manner without altering the viability of the cells. Invasion of OV-MZ-6 cells tested in an in vitro Matrigel invasion 
assay was inhibited by ret-uPAR2r7 up to 75%. In conclusion, these results demonstrate that ret-uPAR tT7 can function as a scavenger for uPA in 
vitro by inhibiting proliferation and invasion of human cancer cells. 
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1. Wroduction 
Urokinase-type plasminogen activator (UPA) is syn- 
thesized and secreted by a variety of normal and malig- 
nant cells. In solution or upon binding to a GPI-an- 
chored high-affinity receptor on the cell surface (uPAR), 
UPA activates plasminogen to plasmin which in turn 
degrades extracellular matrix proteins, such as fibrin and 
fibronectin [1,2]. The binding of uPA and its inhibitor, 
plasminogen activator inhibitor type 1 (PAI-l), induces 
inte~alization of the receptor-uPA-inhibitor complex 
[3] and may lead to the activation of a phosphotyrosine 
kinase [4]. It has also been shown that UPA itself exerts 
cytokine-like activity by increasing the proliferation of 
the prostate cancer cell line, CCL 20.2, or the HL 60 cell 
line [5,6]. 
The uPA-uPAR system is critically involved in the 
invasion and metastasis of cancer. Cells lacking detecta- 
*Cor~spond~ng author. Fax: (49) (89) 4180 5146. 
Abbreviations: UPA, urokinase-type plasminogen activator; uPAR, 
urokinase receptor; ret-UPAR,,, soluble recombinant human uroki- 
nase receptor l-277 lacking the GPI moiety; PA&I, plasminogen acti- 
vator inb~bitor type 1; PBS, pbosphat~b~er~ saline; BSA, bovine 
serum albumin; FITC, fluorescein isothiocyanate; PMSF, phenylmeth- 
ylsulfonylfluoride. 
ble urokinase expression become invasive upon transfor- 
mation with a UPA expression plasmid [I. Furthermore, 
monoclonal antibodies directed against UPA or uPA 
peptides comprising residues 17-32 of the epidermai 
growth factor-like domain of UPA can decrease the inva- 
siveness of cancer cells in vitro [8,9]. In another ap- 
proach, inhibition of metastasis of cancer cells in nude 
mice was achieved by introducing an expression plasmid 
of a proteolytically inactive uPA mutant into cancer 
cells, thereby blocking the UPA-uPAR interaction on the 
cancer cell surface in an autocrine fashion [IO]. 
In this report, we tested whether a soluble, truncated 
uPAR shows the ability to function as a scavenger for 
UPA by inhibiting cell proliferation and invasion of the 
human ovarian cancer cell line, 0%MZ-6. 
2. Materials and methods 
2.1. Cell culture 
The human ovarian cancer cell line, OV-MZ-6, established from a 
patient with cystaden~~cinoma of the ovary as detailed in [1 I], was 
cultured in Falcon Easy Access tissue culture flasks (&ton-Dickinson, 
Heidelberg, Germany). Cells were cultivated in Dulbecco’s modified 
Eagle’s medium in the presence of 10% fetal calf serum, 100 IWml 
penicillin and 100 &ml streptomycin supplemented with 10 mM 
HEPES, 0.27 mM asparagine and 0.55 mM a&nine. The adherently 
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growing cells were su~ultured using 0.05% EDTA in PBS to avoid 
destruction of cell surface antigens. 
2.2. Recombinant truncated soluble urokinase receptor 
The truncated uPAR, comprising amino acids l-277 (ret-uPAR,,,), 
was cloned and expressed as described in detail in [i2]. Ret-uPAR,,, 
was purified from culture su~mat~ts by affinity chromatography as 
outlined in [12] with slight modifications. 125 mg of PMSF-inactivated 
UPA was coupled to CH-Sepharose (Pharmacia, Freiburg, Germany) 
according to the manufacturer’s recommendation. Culture medium 
containing ret-uPAR,,, was passed over the uPA-Sepharose in the 
presence of 1 M NaCl, 1 mM PMSF, 1 mM EDTA and 2000 U/ml 
aprotinin to reduce low affinity interaction of uPA with proteins and 
to inhibit degradation of uPA by proteases present in the culture super- 
natants. Bound ret-uPAR2,, was eluted with 0.2 M acetic acid, pH 2.0 
and stored at this pH at -20°C until use. Prior to its use, purified 
ret-uPAR,,, was dialyzed against PBS, pH 7.4. Protein content was 
determined by the bicinchoninc acid method (Pierce, Rockford, IL, 
USA). The nurified nrotein analvzed bv SDS-PAGE as shown in fl21 
migrates wi;h an apparent mol&ular mass of 50-60 kDa. The thr& 
obvious bands very likely represent different glycosylation variants, 
since all three variants bind to uPA and, in addition, N-terminal amino 
acid sequence analysis revealed only a single amino acid sequence. This 
amino acid sequence was in agreement with the published uPAR se- 
quence [15]. 
2.3. Detection of uPAR on cancer cells 
I@ cells were suspended in 0.5 ml of 50 mM glycine-HCl, containing 
100 mM NaCl, pH 3.0, in order to dissociate receptor-bound uPA from 
its receptor (30 s, 2Z°C), and then neutralized by the addition of 0.5 ml 
of 5 mM HEPES containing 100 mM NaCl. DH 7.5. The cells were 
washed twice with PBS/O.l%BSA. uPAR antigen was detected on the 
cancer cell surface by incubating cells with increasing concentrations 
of monoclonal antibody #3936-(American Diagnostica, Greenwich, 
CT. USAl (range O-2000 &ml) for 30 min at 22°C. After washing 
twice with &Sk.l% BSA aid resuspension in 250 ,ul PBS/O.l% BSA 
cont~n~ng 4,uglml FITC-goat anti-mouse IgG (Sigma, St. Louis, MO, 
USA), the reaction mixture was incubated for 30 min at 22’C. Cells 
were washed as described above and cell-associated fluorescence was 
measured with the FACScan flow cytofiuorometer (Becton Dickinson, 
Heidelberg, Germany). Autofluom~nce and non-specific binding of 
FITS-antibody in the absence of monoclonal antibody #3936 was 
subtracted from total fluorescence. 
Binding of pro-uPA to cell surface uPAR was performed as described 
[t2]. Briefly, cells were treated with 50 mM glycine-HCl, 0.5 M NaCI, 
pH 3.0, to dissociate receptor-bound uPA. After ~nt~fugation, IO6 
cells were resuspended in 1 ml PBS/O. 1% BSA containing 100 ng FITC- 
pro-uPA (30 min, 22’C). Cell associated fluorescence was determined 
without washing the cells (real time analysis) on the FACScan. Non- 
snecific binding of FITC-oro-uPA to cells was determined in the nres- 
1 
ence of 6 @ml @O-fold excess) of parent pro-uPA. The competitor 
ret-uPAR,,, was preincubated (30 min, 22’Cf at different concentra- 
tions (range O-2 fig/ml) with 100 ng/ml of a fixed concentration of 
FITC-pro-uPA before addition to the cells. 
Cellular DNA was stained with propidium iodide (4Oygiml) to verify 
viability of the cells. Cells which stained with propidium iodide were 
not included in the analysis. 
2.4. Profz~eration assay 
Proliferation was analyzed using the Cell Titer 96 non-radioactive 
cell proliferation assay p&chased f&m Promega {Madison, WI, USA). 
The influence of ret-uPART,, on the viability of the cells was deter- _, 
mined by staining cells in parallel experiments with Trypan blue. 
The in vitro invasion of cancer cells was studied in a double-filter 
assav as described F131. Brief& Matrigel (Collaborative Biomedical 
Prochscts, Bedford, MA, USA)was locaied between an upper polycar- 
bonate filter and a lower nitrocellulose filter. 10’ cells in 1 ml cell culture 
medium, with or without ret-uPAR,,,, were applied on top of the filter 
sandwich and incubated for 16 h at 37°C. The whole set-up was fixed 
with glutara~deh~de for 72 h, then disas~mbl~ and the filter stained, 
either with hematoxylin (in the case of the nitrocellulose filters including 
the Matrigel) or with Giemsa’s olution (in the case of the polycarbon- 
ate filter). The invasion rate was dete~i~ed by c~culating the ratio of 
adherent cells on the upper filter and of cells that had invaded into the 
Matrigel and lower filter, 
3. Results and ~scussjo~ 
The present study aimed at investigating whether a 
soluble recombinant uPAR possesses the capability to 
inhibit proliferation and/or invasion of cancer cells by 
acting as a scavenger for uPA. For this purpose, the 
human ovarian cancer cell line, OV-MZ-6, which ex- 
presses uPAR, UPA and its inhibitor, PA&l, was selected 
as the target cell line [14]. Cell surface-bound uPAR was 
detected with a monoclonal antibody (mAb) directed to 
uPAR (#3936) applying flow cytofluorometry. The bind- 
ing of mAb #3936 is dose-dependent; saturation is 
achieved at - 1 @ml mAb #3936 (Fig. 1). A 68fold molar 
excess of soluble ret-uPAR,,, completely abolished bind- 
ing of mAb #3936 to cellular uPAR, demonstrating the 
specificity of the uPAR-~b interaction. 
uPAR on OV-MZ-6 is functionally active. This was 
shown by flow cytofluorometry using fluorescently la- 
beled pro-uPA (FITC-pro-uPA). Binding of FITC-pro- 
UPA (input 100 q/ml) to uPAR on OV-MZ-6 cells was 
inhibited by ret-uPAR,,, (range O-2 &ml) in a concen- 
tration-dependent manner (Fig. 2). Under these condi- 
tions, 50% of FITC-pro-uPA binding was achieved at an 
input of 200 r-&ml of ret-uPAR,,,. Since the molecular 
mass of pro-uPA (54 kDa) and rec-uPAR277 (55 kDa) are 
very close, a 50% inhibition of pro-uPA binding activity 
is thus affected by a two-fold molar excess of rec- 
uPARZ77 over FITC-pro-uPA. Similar results have been 
demonstrated for the promyelocytic cell line, U-937 [ 121. 
uPA-stimulated proliferation of tumor cell lines is 
known to be mediated via binding of uPA to uPAR [5,6]. 
MbodyQJ ~n(~ Imt) 
Fig. 1. Detection of uPAR by mAb #3936 (indirect immunofluores- 
cence) on the human ovarian cancer cell line OV-MZ-6, by flow cyto- 
fluorometry (FACS) as described in detail in section 2. Autofhrores- 
cence of OV-MZ-6 and non-specific binding in the absence of mAb 
#3936 were subtracted from total binding. Fluorescence is expressed 
as relative fluorescence mean channels. 
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Fig. 2. Ret-uPAR,, inhibits binding of fluorescently labeled pro-uPA 
(FITC-pro-uPA) to the living human ovarian cancer cell line, OV-MZ- 
6. Binding of FITC-labeled pro-uPA to OV-MZ6 in the presence of 
various concentrations of ret-uPARz7, was determined by flow cyto- 
fluorometry as described in detail in section 2. The arrow indicates 50% 
inhibition (200 @ml ret-uPAR,,). 
In some cells, enhancement of proliferation is mediated 
by the active enzyme [16], in others by the amino-termi- 
nal fra~ent of UPA (amino acids l-l 58) [17]. This stim- 
ulation of the proliferation is inhibited by chemically 
inactivated uPA or uPA analogues [16,17]. Cells express- 
ing UPA and uPAR show the ability to saturate their own 
cell surface uPAR in an autocrine fashion [18]. Binding 
of endogenous UPA to OV-MZ-6 cells triggers cell prolif- 
eration. The addition of ret-uPAR,,, (24 h exposure) 
si~ificantly reduced proliferation of 0%MZ-6 cancer 
cells in a dose-dependent manner (Fig. 3). Viability of 
OV-MZ-6 cells was una~ected by di~erent ret-uPAR,,, 
concentrations, as verified by Trypan blue exclusion. 
A second biological effect of rec-uPARzTT on the UPA- 
uPAR interaction was demonstrated by an in vitro inva- 
sion assay. Ret-uPAR,,, inhibited invasion of OV-MZ-6 
at 10 ,@ml by 50% and at 20 &ml by 75%. The adhe- 
sion capacity of OV-MZ-6 cells was, however, not signif- 
icantly altered. At 20 &ml ret-uPAR2?,, the invasion of 
OV-MZ-6 was inhibited by 75% but proliferation only 
by 29%. This clearly demonstrates that the reduced inva- 
sion capacity of 0%MZ-6 in the presence of rec- 
uPARzT7 observed in the in vitro invasion assay is an 
additive effect of inhibition of cell proliferation and inva- 
sion uPA-dependent umor cell invasion was already 
shown by others. In vitro tumor cell invasiveness was 
inhibited si~ificantly by mAb’s to UPA [B] or UPA pep- 
tides comprising residues 17-32 of the epidermal growth 
factor domain of UPA [9]. We demonstrate that not only 
uPA analogues or mAb’s are able to influence the inva- 
sion of cancer cells but also ret-uPAR,,,. 
OV-MZ-6 cells express both UPA and its inhibitor, 
PAI- [i4]. Stimulation of tumor cell proliferation might 
be the result of internalization of the uPAR-uPA-PAI- 
complex. Indeed, in breast cancer patients, elevated 
0 
Fig. 3. Effect of ret-uPAR,,, on the proI~feration of the human ovarian 
cancer cell line, OV-MZ-6. Mean values of three experiments are 
shown, standard deviation is less than 10% for each data point. 
uPA-PAZ-1 values are associated with increased S- 
phase, a measure of cell proliferation [19]. The addition 
of excess rec-uPARz7? to OV-MZ-6 resulted in binding 
of UPA and/or UPA complexed with PAI- leading to a 
reduction of cell surface uPA activity and, thus, to a 
decrease in cell-associated plasmin activity by preventing 
activation of plasminogen to plasmin PO]. The degrada- 
tion of extracellular matrix proteins by plasmin, which 
facilitates cancer cell invasion, is therefore subsequently 
reduced. 
In conclusion, a soluble r~ombinant truncated form 
of the urokinase receptor is able to block binding of uPA 
to cell surface-bound uPAR. Consequently, rec-uPAR277 
functions as a scavenger for UPA by inhibiting UPA- 
induced tumor cell proliferation and invasion of the OV- 
MZ-6 ovarian cancer cell line into the Matrigel. On the 
basis of these results we propose that in addition to uPA 
analogues and r&b’s to UPA, rec-uPARzT7 is a putative 
candidate for treatment of cancer spread. Nevertheless, 
inhibition of tumor growth and metastasis in vivo should 
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Fig. 4. inhibition of the invasion of OV-MZ-6 cells by ret-uPAF& 
determined by an in vitro invasion assay. Mean values zk SD. of three 
experiments are indicated. 
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be demonstrated by animal experiments (e.g. nude mice) 
which still awaits verification. 
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